Skip to content

Effect of different anesthesia techniques on intraoperative stress-induced immunosuppression in patients undergoing radical esophagectomy'

Evaluation of whether different anesthesia techniques can affect intraoperative stress-induced immunosuppression in patients undergoing radical esophagectomy.

Status
Completed
Phases
Unknown
Study type
Interventional
Source
ANZCTR
Registry ID
ACTRN12617000434392
Enrollment
40
Registered
2017-03-24
Start date
2015-05-06
Completion date
2015-09-18
Last updated
2017-04-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Brief summary

With exposure to severe food safety issues especially in China, the global incidence of cancer has risen dramatically, although survival rate of cancer patients is improving due to the modern medical technology, cancer is the second most common cause of death, exceeded only by heart disease and accounting for one in every four deaths. Although surgery remains the most effective treatment of potentially curable solid tumors, anesthesiologists shoulder the responsibility to minimize worsen fragile immune function of cancer patients in perioperative period. The trial which investigated whether different anesthesia techniques could affect intraoperative stress-induced immunosuppression in patients undergoing radical esophagectomy has significant clinical practical significance and this trial is fully in line with the Declaration of Helsinki human trials, so the ethics committee unanimously supported the trial adoption.

Interventions

Patients undergoing radical esophagectomy were randomly assigned to one of the two groups. In group I (n=20), patients received total intravenous general anesthesia (Group TIVA); in group II (n=20), patients received total intravenous general anesthesia combined with thoracic epidural anesthesia (Group TIVA+TEA). Each test solution was prepared in a syringe by the first investigator, who was also responsible for subject grouping. Under sterile conditions, a thoracic epidural catheter was placed

Patients undergoing radical esophagectomy were randomly assigned to one of the two groups. In group I (n=20), patients received total intravenous general anesthesia (Group TIVA); in group II (n=20), patients received total intravenous general anesthesia combined with thoracic epidural anesthesia (Group TIVA+TEA). Each test solution was prepared in a syringe by the first investigator, who was also responsible for subject grouping. Under sterile conditions, a thoracic epidural catheter was placed via the T7–8 interspace and was advanced 3–4 cm cephalad by the first investigator. A test dose of 1% lidocaine 5 mL, alone, was then given by the first investigator via the thoracic epidural catheter, followed by 0.375% ropivacaine 5 mL, to produce a bilateral segmental sensory block to pinprick between the T6 and L4 dermatomes, or given 10mL normal saline. Then neuraxial block was maintained with 0.375% ropivacaine 5 mL/h or normal saline 5 mL/h throughout the surgical procedure by the second anaesthesiologist. Entropy index was used to maintain the depth of anesthesia to a certain level. Plasma levels of stress hormones and cytokines were assessed before surgery and as well as 1 and 3 hours after the beginning of surgery.

Sponsors

National Natural Science Foundation of China
Lead SponsorGovernment body

Study design

Allocation
Randomised controlled trial
Intervention model
Parallel
Primary purpose
Treatment
Masking
Blinded (masking used) (Subject, Caregiver)

Eligibility

Sex/Gender
All
Age
29 Years to 78 Years
Healthy volunteers
No

Inclusion criteria

40 patients, of ASA physical status 1-3 adult patients, undergoing elective surgery for radical esophagectomy were included in this prospective randomized, double-blind, placebo-controlled trial.

Exclusion criteria

contraindications for receiving TEA, pre-existing cardiovascular diseases, preoperative treatment with opioids, non-steroidal anti-inflammatory drugs, or other immunomodulatory substances, infection, immune and endocrine system disorders and communication barriers.

Outcome results

None listed

Source: ANZCTR · Data processed: Feb 4, 2026